Selective elimination of Human Epidermal growth factor Receptor 2 (HER2)-positive EVs, which are known to interfere with drug efficacy and promote tumor progression, has shown therapeutic benefit in HER2-positive breast cancer, supported by in vitro and in vivo models [110]. The gene discussed is ERBB2; the disease is neoplasm.